Control and IPF fibroblasts (n=8, each) used for cell viability assay (6 × 105 cells/60 mm cell culture dish) were treated with cisplatin for various time points. Cells were lysed with 1x cell lysis buffer (Cell Signaling technology, Beverly, MA) containing protease inhibitor (Roche Applied Science, Indianapolis, IN) and phosphatase inhibitor (Research Products International Corp., Mount Prospect, IL), and western blotting was performed as previously described (15 ,16 (link),17 (link)). The antibodies used for our study are: γH2AX (PRID: AB_2118009, Cell Signaling Technology) (21 (link)), H2AX (RRID: AB_10694556, Cell Signaling technology) (22 (link)), RAD51 (RRID: AB_2042762, Abcam, Cambridge, UK) (11 (link)), BRCA2 (RRID: AB_2259370; R&D systems, Minneapolis, MN) (11 (link)), pXRCC1 (phosphorylated at S518, T519, and T523; catalog No. ab195205; Abcam) (21 (link)), XRCC1 (RRID:AB_10985840; ThermoFisher Scientific, Pittsburgh, PA) (23 (link)), CK2α (catalog No. 2656; Cell Signaling technology)(24 (link)), PUMA (RRID:AB_10987708; Santa Cruz Biotechnology, Santa Cruz, CA)(25 (link)), or GAPDH (RRID:AB_627679; Santa Cruz Biotechnology) (26 (link)). The protein bands on a membrane were then detected by ECL solution (ThermoFisher Scientific) using Chemi Doc-IT2 image analyzer (UVP BioImage systems, Upland, CA), and quantified using VisionWorks LS program (UVP BioImage systems).